GAMMA Investing LLC Has $397,000 Stake in Kenvue Inc. (NYSE:KVUE)

GAMMA Investing LLC lifted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 17.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,609 shares of the company’s stock after acquiring an additional 2,719 shares during the quarter. GAMMA Investing LLC’s holdings in Kenvue were worth $397,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in KVUE. Riverview Trust Co acquired a new position in Kenvue in the 3rd quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue during the third quarter worth approximately $35,000. Versant Capital Management Inc grew its position in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares during the last quarter. Studio Investment Management LLC increased its stake in shares of Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after purchasing an additional 845 shares during the period. Finally, Deseret Mutual Benefit Administrators increased its stake in shares of Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after purchasing an additional 651 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock opened at $21.08 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market cap of $40.42 billion, a PE ratio of 38.33, a price-to-earnings-growth ratio of 2.02 and a beta of 1.46. The company has a 50 day moving average of $22.81 and a 200-day moving average of $21.53. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company earned $0.31 earnings per share. As a group, equities research analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.89%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on KVUE shares. Barclays upgraded Kenvue to a “hold” rating in a research note on Thursday, December 12th. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $21.00 to $26.00 in a research report on Monday. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $23.09.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.